Alkermes

ALKS · NASDAQ

$44.11+$1.14 (+2.65%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $42.97

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.

Employees: 2,050
Headquarters: DUBLIN, Dublin
Listed: Jul 16, 1991
Sector: Health Care
Industry: Biotechnology
Website: alkermes.com

Leadership

Alkermes executives
Name	Title	Since	Age
Richard Pops	—	2011	63
Joshua Reed	—	—	52
Blair Jackson	—	—	53
David Gaffin	—	—	53
Craig Hopkinson	—	—	57
C. Todd Nichols	—	—	56
Frank Wilson	—	—	67
Shane Cooke	—	2011	62
Richard Gaynor	—	—	75
Cato Laurencin	—	—	66
Nancy Lurker	—	—	67
Brian Mckeon	—	—	63
Nancy Snyderman	—	—	73
Christopher Wright	—	—	59

Revenue by product and region

Fiscal year ended Dec 31, 2024: $1.56B total revenue

By product

Product [Member]$1.08B69.6%
Article or substance produced by labor or machinery, and royalties.$474.10M30.4%
Relating to research and development.$3.00K0.0%

By region

UNITED STATES$1.41B90.5%
Represents designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile, excluding the specified country.$146.18M9.4%
IRELAND$1.29M0.1%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Alkermes suppliers and customers
Company	Relationship	Country	Correlation
Cambridge Cognition Hldgs COG.L	Supplier	GB	0.37
Johnson & Johnson JNJ	Supplier and customer	US	0.36
Certara CERT	Supplier	US	0.35
Amneal Pharmaceuticals A AMRX	Supplier and customer	US	0.34
Acceleron Pharma Inc. XLRN	Supplier and customer	US	0.33
Acorda Therapeutics ACOR	Supplier and customer	US	0.28
Biogen BIIB	Supplier and customer	US	0.20
Baudax Bio BXRX	Supplier and customer	US	0.19
Veeva Systems A VEEV	Supplier	US	0.14
AmerisourceBergen ABC	Supplier and customer	US	0.05

Similar companies

Companies in the same industry as Alkermes

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.